CNBC's Bertha Coombs reports which insurance stocks are feeling the pressure from high drug costs. FMHR trader Stephen Weiss advises investors to stick with Gilead.» Read More
Two years after hurricanes Katrina and Rita swamped New Orleans, the recovery efforts have created a tale of two cities … and it is doubtful that the full grandeur of the old Crescent City will ever arise from either one of them.
Novo Nordisk, the world's biggest diabetes drug company, is very lightly traded on the New York Stock Exchange, but check out the move in the stock today. Coincidentally, on the day that The New York Times runs a front-page story (with two jump pages) on how controlling diabetes is about lowering blood sugar and cholesterol levels, the Danish drugmaker is out with major data on its glucose fighting drug Liraglutide.
QBE Insurance Group, Australia's top insurer by premium income, reported a higher-than-expected first-half profit on U.S. acquisitions, and upgraded its insurance profit forecast.
Two things have happened recently that made me realize we are at the "tipping point" of environmental awareness. One is that my company began implementing some green initiatives - a company whose rubbish bins were often filled with styrofoam cups and lunch boxes and where dozens of television and computer monitors used to hum ceaselessly overnight. The other is that Live Earth was a total flop audience-wise. Not because people were unaware of the need to protect the environment, but because everyone, including people like me, had already heard enough about it. Eighteen years after Time magazine put "Endangered Earth" on its cover, yeah, we do finally get it.
Ping An Insurance, China's second-largest life insurer, posted a 140% gain in first-half profit late on Thursday, driven by a contribution from its banking operations and strong investment returns amid a booming domestic stock market.
Net profit at insurer Zurich Financial Services surged 33% in the first half of the year, beating market expectations despite heavy flooding in the U.K., the company reported Thursday.
BioMedTracker, which monitors drug development for investors, ran some numbers for me. As of August 13th, how does the number of FDA-approved drugs and "approvable" drugs compare to the same period a year ago? According to the company, drug approvals are down 16% and approvable letters are up 55%. An approvable letter is what the FDA issues when it believes it might someday okay a drug, but only if a company provides additional -- often publicly unspecified -- data. So, for investors, "approvable" is a euphemism for delay.
While the rest of the market is struggling with liquidity issues, at least one sector isn't having trouble generating cash.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
Bryan Gaffin, VP, Group Creative Director at G2 Direct & Digital writes to say that his division and not G2 Branding & Design is responsible for the new Pfizer website. They're part of the same company, WPP Group, but separate divisions. Credit where credit is due.
Dutch insurer Aegon said has agreed to buy Merrill Lynch Life Insurance and ML Life Insurance of New York for $1.3 billion in cash to boost its sales of variable annuities and distribution in the United States.
Burlington Northern shares are picking up speed on Wall Street, after Warren Buffett added to his bet on the railroad. Buffett's apparent optimism on the rails gives Fast Money's Guy Adami an idea. PLUS: Why Geico's Gecko may be going back to Massachusetts.
Insurance broker Marsh & McLennan said Tuesday quarterly earnings edged higher on revenue growth but missed forecasts, as operating expenses not related to compensation and benefits rose.
Second-quarter net profit at Swiss Re rose by 45%, in line with expectations, and the reinsurer said on Tuesday it saw a strong outlook for the rest of the year.
Germany's Munich Re on Monday reported a 2.2% increase in second-quarter net profit, beating expectations as a lower tax rate offset lower premiums, lower capital investment gains and higher claims.
Allianz, Europe's biggest insurer, beat forecasts with net profit of 2.140 billion euros ($2.9 billion) in the second quarter, down 6% from a year earlier when the result was boosted by asset sales.
So, I just got off the Pozen conference call about the Trexima delay (by the way, it won't be called Trexima if/when it comes to market, as the FDA is asking Glaxo for a name change. The agency sometimes does this if, for example, it believes the name looks or sounds too much like an existing drug and could confuse pharmacists.)
From healthcare to real estate to retirement, there are many steps you can take to spend less and save more.
The chief executive of Humana told CNBC that the company's recent quarterly performance was the best he has seen during his tenure and expects the company to capitalize on further growth opportunities."In my seven years as CEO this is probably the best quarter we've had," president and CEO Michael McCallister said in an interview.
Aetna Thursday posted a 16% rise in second-quarter earnings as enrollment increased, and the No. 3 U.S. health insurer raised its full-year forecast.
British insurer Legal & General announced plans on Thursday for a 1 billion pound ($2.1 billion) share buyback and boosted its dividend growth rate to 7.5%, alongside a 5% rise in first-half profit.
Get the best of CNBC in your inbox